Myoview (Tetrofosmin)

Tetrofosmin, the active ingredient in Myoview, is a radiopharmaceutical presented as an injectable solution for intravenous use. It is employed in myocardial perfusion imaging to evaluate coronary artery disease, detect perfusion defects, and assess myocardial viability in adult patients.

GNH USA supplies Myoview as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, and diagnostic imaging clinics worldwide. The product is manufactured under EU GMP standards and distributed to health‑care facilities across Europe, Asia and the Americas, ensuring consistent quality and traceability.

Myoview (tetrofosmin) is used in nuclear cardiology to assess myocardial perfusion and coronary artery disease.

Myocardial perfusion imaging: Enables visualization of regional blood flow to identify perfusion defects. Coronary artery disease detection: Helps locate areas of reduced perfusion caused by obstructive lesions. Myocardial viability assessment: Differentiates viable from non‑viable myocardium for revascularisation planning. Stress testing: Provides images during pharmacologic stress to evaluate inducible ischemia. Rest imaging: Allows comparison of rest and stress perfusion for comprehensive assessment.

Adverse reactions to Myoview are generally related to the radiopharmaceutical nature of tetrofosmin and its intravenous administration.

Common Side Effects: - Nausea - Headache - Flushing - Pain at the injection site

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Hypotension - Cardiac arrhythmia

Myoview should be used with caution in specific patient populations and clinical situations.

Pregnancy: Use only if the potential diagnostic benefit outweighs the radiation risk to the fetus. Breastfeeding: Not recommended; consider withholding breast milk for an appropriate period. Renal impairment: Evaluate renal function; altered clearance may affect image quality. Thyroid disorders: Assess thyroid status as iodine‑based radiotracers can affect thyroid function. Allergy: Discontinue immediately if signs of hypersensitivity occur. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Myoview may interact with other agents that influence radiation exposure or myocardial uptake.

Major Interactions (Avoid): - Concurrent use of other radiopharmaceuticals may increase cumulative radiation dose. - Beta‑blockers may reduce myocardial uptake of tetrofosmin.

Moderate Interactions (Monitor Closely): - Calcium channel blockers may alter distribution of the tracer. - Thyroid hormone therapy may affect radiotracer uptake. - Amiodarone may modify myocardial uptake patterns.